Interruptions of oncedaily thoracic radiotherapy do not. Combination chemotherapy in treating patients with stage. Pulmonary toxicity in stage iii nonsmall cell lung cancer patients treated with highdose 74 gy 3dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy. Interruptions of oncedaily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer. Calgb failed to meet its primary endpoint of os cetuximab is not superior to avastin in 1l kraswt. Calgb 30610 thoracic radiotherapy for limited stage small cell. This is a randomized phase ii trial for patients with localized, surgically resectable esophageal cancer designed to evaluate the early assessment of response to chemotherapy by metabolic. Calgb 30610, a phase iii randomized controlled trial, was designed to compare three accepted regimens including 45 gy in 30 twicedaily fractions over 3 weeks, 70 gy in 35 daily fractions over seven weeks, and 61. Burkitt lymphoma part 1 of 3 the selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. A randomized phase ii trial of myeloablative versus nonmyeloablative consolidation chemotherapy for newly diagnosed primary cns bcell lymphoma arm 1 and arm 2 receive the same induction therapy cycles 15.
Patients not able to be treated within 3 days of day 22 should not be registered to calgb 30610. Management of all in adults national cancer institute. Pulmonary toxicity in stage iii nonsmall cell lung cancer. Treated with combination chemotherapy calgb lung nct00698815 pemetrexed andor sunitinib as second. Phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide protocol informationlink to clinicaltrials. Bhs guidelines for the treatment of burkitts lymphoma. Failing to do all of the above will make the patient not eligible for calgb 30610. Ea11 a randomized phase iii postoperative trial of platinum based chemotherapy vs.
Registration to calgb 30610 must take place within 1421 days after the start of the nonprotocol therapy. This situation might change if the ongoing phase 3 trial calgb 30610 nct00632853, comparing 45 gy twicedaily with 70 gy oncedaily in the usa, reaches different conclusions. Calgb 10603ctsu c10603 2 040108 calgb central office 230 west monroe street, suite 2050 chicago, il 606064703 tel. Prophylactic cranial irradiation overview collaborative group. Patients with direct invasion of the vertebral bodies or. Calgb 30610 rtog 0538 limited small cell 45 gy bid 3 weeks 61. Announcements from nci and the lpos will be posted as they are received. Christakis, for the cancer and leukemia group b, measuring diseasefree survival and cancer relapse using medicare claims from calgb breast cancer trial participants companion to 9344, jnci. A phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia. Patients may be registered to calgb 30610 following one cycle of chemotherapy.
Calgb 30610, phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide protocol version date092717 v. Phase iii comparison of thoracic radiotherapy regimens in. Multimodality therapy for limitedstagesmallcelllungcancer. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and. To download the pdf, click the download link below. Acute leukemia group b, algb is a cancer research cooperative group in the united states calgb research is focused on seven major disease areas. Calgb 30105 eligibility criteria have been published previously. Rtog 0539 radiation therapy oncology group rtog 0539 phase ii trial of observation for lowrisk meningiomas and of radiotherapy for intermediate and highrisk meningiomas study chairs 6910. Calgb 30610rtog 0538 started as a 3 arm study designed to discontinue one of 2 ex. Radiation therapy regimens in treating patients with limited. Calgb 30610 phase ill comparison of thoracic radiotherapy regimens with cisplatin and etoposide in limited small cell lung cancer patient eligibility histologically or cytologically documented small cell lung cancer of limited stage see section 4. Three different radiation therapy regimens in treating.
Calgb 30610 phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide. Failing to do all of the above will make the patient not eligible for calgb. Calgb 80405 pdf asco, itt, kraswt primary os results. Additional information from nci is available on the ctep coronavirus guidance page. Ea6141, randomized phase iiiii study of nivolumab plus ipilimumab plus sargramostim. Rtog 0538calgb 30610 protocol student doctor network. Listing a study does not mean it has been evaluated by the u. Patients may have received one and only one cycle of chemotherapy prior to enrolling on cancer and leukemia group b calgb 30610, which must have included carboplatin or cisplatin and etoposide. Measuring diseasefree survival and cancer relapse using. Failing to do all of the above will make the patient not. Combination chemotherapy in treating patients with stage iii colon cancer the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Use the covid19 button located at the top of the ctsu members website to access the covid19 information page.
We encourage the study authors to analyse quality of life data for patients as well as caregiver burden, and other research groups to conduct a formal economic analysis. Leukemia group b trials calgb 30904 reported that total. Calgb 30610 rtog 0538 piyunjie lin, md nct 00632853 coordinatorangie patterson a phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide hcrn lun17302 pi maitri kalra, md nct 039455 coordinatorangie patterson. Lsclc treated on the experimental thoracic radiotherapy trt arms of calgb 30610 alliance rtog 0538. Calgb 30610 pdf phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide. No prior radiotherapy or chemotherapy except for the chemotherapy described in the bullet above for sclc. Briefly, patients with histologically or cytologically confirmed stage iiiaiiib ajcc 2000 unresectable nsclc, eastern cooperative oncology group ecog performance status ps of 01, and normal organ and marrow function were eligible. Smallcell lung cancer sclc represents 10% to 15% of lung cancer cases and. Patients must receive the second cycle of therapy following registration, on day 2224, so that the patient adheres to a 3week treatment cycle. Calgb 100104 2 111511 calgb central office 230 west monroe street, suite 2050 chicago, il 606064703 tel. Interim toxicity analysis for patients with limited stage small cell lung. A phase ii study of dasatinib and dexamethasone as primary.
Calgb 30610 phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide a151216 adjuvant lung cancer enrichment marker identification and sequencing trial alchemist a081105 randomized double blind placebo controlled study of. Line therapy in treating patients with stage iiib or stage iv non. Adjuvant lung schema protocol informationlink to clinicaltrials. A pediatric regimen for older adolescents and young adults. Interim toxicity analysis for patients with limited. Indiana university health ball memorial cancer center. The pdf file you selected should load here if your web browser has a pdf reader plugin installed for example, a recent version of adobe acrobat reader. Is it time to convert the frequency of radiotherapy in. Radiation dose and fractionation for limitedstage smallcell lung. Radiation therapy regimens in treating patients with. Checklist for submission of radiation oncology quality assurance materials. Prophylactic cranial irradiation for patients with smallcell lung cancer in complete remission. Impact of induction chemotherapy on estimated risk of.